Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OMCL
BUYOmnicell, Inc. · Healthcare · United States · $1.9B · Avg Vol: $31M/d
COMPANY DESCRIPTION
Omnicell, Inc. is a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies globally. The company offers automated dispensing systems, medication adherence packaging, and analytics software, enhancing efficiency and patient safety in medication workflows. Omnicell's integrated platform and advanced automation technology create a significant competitive advantage in the healthcare IT and pharmacy automation market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.3B | 1.1B | 1.1B | 1.2B | -2.9% | 1.2B | 1.2B | 1.3B | 5.4% |
| EPS | 0.13 | -0.45 | 0.27 | 0.04 | -32.5% | 0.43 | 0.05 | 0.05 | 16.4% |
| Shares | 44.7M | 45.5M | 46.4M | 45.0M | +0.6% | 45.5M | — | — | — |
| Debt | 616.7M | 614.1M | 382.5M | 204.3M | -30.8% | 202.2M | — | — | — |
| Equity | 1.1B | 1.2B | 1.2B | 1.2B | 2.9% | — | — | — | — |
| Op CF | 77.8M | 181.1M | 187.7M | 127.3M | 17.8% | 155.9M | — | — | — |
| Inv CF | -58.7M | -55.0M | -52.8M | -60.4M | — | — | — | — | — |
| Fin CF | -21.0M | 23.4M | -235.6M | -218.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OMCL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OMCL | Omnicell, Inc.(you) | $1.9B | 65 | BUY |
| OMDA | Omada Health, Inc. | $1.2B | 63 | HOLD |
| TDOC | Teladoc Health, Inc. | $1.6B | 76 | BUY |
| TALK | Talkspace, Inc. | $873M | 65 | HOLD |
| PRVA | Privia Health Group, Inc. | $3.2B | 59 | HOLD |
| DOCS | Doximity, Inc. | $3.7B | 62 | HOLD |
| WAY | Waystar Holding Corp. | $4.3B | 64 | HOLD |
| CERT | Certara, Inc. | $1.2B | 53 | HOLD |
| GDRX | GoodRx Holdings, Inc. | $1.0B | 76 | BUY |
| MDRX | Veradigm Inc. | $517M | 66 | BUY |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.7%